發(fā)布時間：2018-09-12 16:45

【摘要】：目的:評價兩種方案治療宮頸癌骨轉(zhuǎn)移患者的療效及毒副反應(yīng)。方法:回顧性收集資料完整的宮頸癌骨轉(zhuǎn)移患者56例,按治療方案分為放化療組(31例)和雙膦酸鹽組(25例),放化療組患者采用放、化療聯(lián)合雙膦酸鹽治療,雙膦酸鹽組采取雙膦酸鹽姑息對癥治療,3~4周為1個療程,兩組患者均治療3個療程。比較兩組患者平均生存時間、生存質(zhì)量及毒副反應(yīng)。結(jié)果:宮頸癌骨轉(zhuǎn)移后放化療組患者平均生存時間為17月(95%CI:9.1~24.9),雙膦酸鹽組為19月(95%CI:2.4~35.6);3年生存率放化療組患者為16.1%,雙膦酸鹽組為16.0%,組間比較差異均無統(tǒng)計學(xué)意義(P=0.820)。3個療程后患者KPS評分比較,放化療組患者改善率(22.6%)明顯低于雙膦酸鹽組(40.0%),差異有統(tǒng)計學(xué)意義(χ2=4.36,P0.05);放化療組毒副作用較雙膦酸鹽組明顯。結(jié)論:雙膦酸鹽對患者生存質(zhì)量影響較小,毒副反應(yīng)不明顯,臨床上值得推薦給部分晚期、高齡、復(fù)發(fā)的宮頸癌轉(zhuǎn)移患者。
[Abstract]:Objective: to evaluate the efficacy and toxicity of two regimens in the treatment of cervical cancer with bone metastasis. Methods: a total of 56 patients with bone metastasis from cervical cancer were retrospectively collected and divided into radiotherapy and chemotherapy group (31 cases) and bisphosphonate group (25 cases). The patients in the radiotherapy and chemotherapy group were treated with radiotherapy and chemotherapy combined with bisphosphonate. Bisphosphonate group was treated by palliative treatment with bisphosphonate for 3 weeks as a course of treatment, and the two groups were treated for 3 courses. The mean survival time, quality of life and toxicity were compared between the two groups. Results: the mean survival time was 17 months (95%CI:9.1~24.9) and 19 months (95%CI:2.4~35.6) in the radiotherapy and chemotherapy group after bone metastasis, while the survival rate was 16. 1 in the radiotherapy and chemotherapy group and 16. 0 in the bisphosphonate group. There was no significant difference among the three groups (P0. 820). Comparison of KPS scores of patients after course, The improvement rate of radiotherapy and chemotherapy group (22.6%) was significantly lower than that of bisphosphonate group (40.0%), the difference was statistically significant (蠂 2 / 4.36 P 0.05), and the side effect of radiotherapy and chemotherapy group was more obvious than that of bisphosphonate group. Conclusion: bisphosphonates have little effect on the quality of life and have no obvious side effects. It is recommended to some advanced, advanced and recurrent cervical cancer metastasis patients clinically.
【作者單位】： 重慶市腫瘤研究所;
【分類號】：R737.33

【共引文獻(xiàn)】

相關(guān)期刊論文 前2條

1 周亭芳;李高峰;李朵;崔迎紅;楊小紅;曹建國;羅瓊;;白楊素增強輻射誘導(dǎo)宮頸癌HeLa細(xì)胞系球形成細(xì)胞凋亡[J];湖南師范大學(xué)學(xué)報(醫(yī)學(xué)版);2015年03期

2 顧偉杰;施國海;常坤;韓成濤;戴波;張海梁;朱耀;沈益君;朱一平;葉定偉;;腎細(xì)胞癌肝、骨轉(zhuǎn)移對舒尼替尼靶向治療患者的預(yù)后影響[J];臨床泌尿外科雜志;2015年06期

相關(guān)博士學(xué)位論文 前1條

1 毛丹;乳腺癌骨轉(zhuǎn)移中醫(yī)證候規(guī)律調(diào)查及陽和湯干預(yù)陽虛證乳腺癌骨轉(zhuǎn)移裸鼠模型的實驗研究[D];湖南中醫(yī)藥大學(xué);2014年

【相似文獻(xiàn)】

相關(guān)期刊論文 前5條

1 馬紹康，張曙;宮頸癌骨轉(zhuǎn)移144例分析[J];實用婦產(chǎn)科雜志;1994年05期

2 楊琳琳;楊宏英;張紅平;楊謝蘭;;宮頸癌骨轉(zhuǎn)移48例臨床分析[J];現(xiàn)代腫瘤醫(yī)學(xué);2012年05期

3 李s，

本文編號：2239615